En esta página
01KLRS precio
02Instantánea
03Gráfico
04Divisiones de acciones
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
26Mis Métricas
KLRS Kalaris Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 11, 2026
$2,70
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$2,51mínimo 52 semanas
$11,55máximo 52 semanas
Capitalización Bursátil (MRQ)
$64M
P/E
-0.9
BPA
$-2.85
tus insignias
Rango 52S
$3–$12
Calificación del Analista
STRONG BUY
Precio Objetivo
$19
P/E
-0.9
ROE
-65.8%
Margen de Beneficio Neto
·
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
KLRS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$2.70
Capitalización Bursátil (MRQ)
$64M
P/E
-0.9
BPA
$-2.85
ROE
-65.8%
Rango 52S
$3–$12
KLRS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Divisiones de acciones
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 16 de enero de 2025 | 1-for-23 | Inversa |
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos·2019-12-31 → 2019-12-31
BPA$-2.852021-12-31 → 2025-12-31
Flujo de caja libre$-39M2020-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | KLRS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | -0.9promedio 5A ≈-33.2 | ≈-33.2 | · | · | |
| P/C (MRQ) | 1.1promedio 5A ≈16.0 | ≈16.0 | 1.3 | Más caro | |
| Price / FCF (Precio / FCF) | -1.6 | · | · | · | |
| Price / Cash Flow (Precio / Flujo de Caja) | -1.6promedio 5A ≈-24.4 | ≈-24.4 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 0.8promedio 5A ≈45.1 | ≈45.1 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | KLRS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| ROA | -67.9%promedio 5A ≈-61.8% | ≈-61.8% | -69.2% | En línea | |
| ROE | -65.8%promedio 5A ≈-184.8% | ≈-184.8% | -72.9% | En línea | |
| ROIC | -58.6%promedio 5A ≈-82.4% | ≈-82.4% | -70.9% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | KLRS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 11.0promedio 5A ≈12.9 | ≈12.9 | 3.3 | Liquidez sólida | |
| Quick Ratio (Ratio Rápido) | 12.1promedio 5A ≈12.7 | ≈12.7 | 3.2 | Liquidez sólida | |
| Interest Coverage (Cobertura de Intereses) | -32.0 | · | -32.0 | En línea |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-21.7%
Próximo informe
Nov 10, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 19, 2026 | $-0.48 | $-0.50 | 4.9% |
| 31 de marzo de 2026 | May 20, 2026 | $-0.46 | $-0.53 | 13.8% |
| 31 de diciembre de 2025 | $-0.51 | $-0.54 | 5.9% | |
| 30 de septiembre de 2025 | $-0.64 | $-0.67 | 3.9% | |
| 30 de junio de 2025 | $-0.61 | $-0.53 | -15.0% | |
| 31 de marzo de 2025 | $-2.52 | $-0.79 | -218.8% | |
| 30 de junio de 2024 | $-1.15 | $-2.46 | 53.3% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $165.0K | |
| R&D Expense | $31M | $45M | $133M | $119M | $121M | $50M | $16M | |
| SG&A Expense | $15M | $7M | $48M | $52M | $49M | $22M | $11M | |
| Operating Expenses | $46M | $52M | $200M | $171M | $170M | $71M | $27M | |
| Operating Income | $-46M | $-52M | $-200M | $-171M | $-170M | $-71M | $-27M | |
| Interest Expense | $1M | $3M | · | · | · | · | · | |
| Interest Income | · | $5M | $6M | $2M | $1M | $1M | $2M | |
| Other Non-op | $3M | $188.0K | $4M | $351.0K | $-2M | $195.0K | $797.0K | |
| Pretax Income | $-43M | $-69M | $-191M | $-169M | $-171M | $-70M | $-24M | |
| Income Tax | $0 | $0 | $-126.0K | $-265.0K | $1M | · | · | |
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | $-24M | |
| EPS (Basic) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| Shares (Basic) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| Shares (Diluted) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| EBITDA | $-46M | $-65M | $-200M | $-170M | · | $-71M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98M | $2M | $90M | $106M | $202M | $123M | $61M | |
| Short-term Investments | $20M | $0 | $94M | $128M | $46M | $234M | $65M | |
| Prepaid Expense | $827.0K | $967.0K | $3M | $7M | $5M | $5M | $676.0K | |
| Current Assets | $119M | $3M | $188M | $243M | $253M | $361M | $127M | |
| PP&E (Net) | · | · | · | $930.0K | $2M | $812.0K | $350.0K | |
| PP&E (Gross) | · | · | $2M | $2M | $2M | $904.0K | $369.0K | |
| Accum. Depreciation | · | · | · | $1M | $281.0K | $92.0K | $19.0K | |
| Other Non-current Assets | $953.0K | $410.0K | $122.0K | $612.0K | $1M | · | · | |
| Total Assets | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Accounts Payable | $1M | $2M | $7M | $3M | $8M | $963.0K | $630.0K | |
| Accrued Liabilities | · | $5M | $10M | $14M | $20M | $8M | $5M | |
| Current Liabilities | $10M | $25M | $28M | $24M | $38M | $12M | $9M | |
| Capital Leases | $1M | $0 | $17M | $28M | $23M | $5M | $9M | |
| Total Liabilities | $43M | $57M | $45M | $53M | $61M | $18M | $18M | |
| Common Stock | $2.0K | $0 | $0 | $9.0K | $7.0K | $7.0K | · | |
| Paid-in Capital | $239M | $20M | $802M | $691M | $522M | $478M | $4M | |
| Retained Earnings | $-160M | $-117M | $-656M | $-466M | $-297M | $-125M | $-55M | |
| AOCI | $6.0K | $0 | $-62.0K | $-468.0K | $-155.0K | $-112.0K | $68.0K | |
| Stockholders' Equity | $79M | $-97M | $-45M | $225M | $225M | $353M | $-52M | |
| Liabilities + Equity | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Shares Outstanding | 22,902,418 | 1,356,431 | 4,962,997 | 93,093,243 | 63,565,886 | 61,931,255 | 2,099,740 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K | |
| Stock-based Comp | $2M | $895.0K | $41M | $41M | $44M | $9M | $3M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $10M | · | · | · | · | · | |
| Other Non-cash | · | · | $25M | $-15M | · | $-529.0K | · | |
| Operating Cash Flow | $-38M | $-21M | $-124M | $-142M | $-106M | $-61M | $-20M | |
| CapEx | $200.0K | · | · | · | $26.0K | $235.0K | $339.0K | |
| Investing Cash Flow | $-20M | $95M | $38M | $-80M | $186M | $-169M | $-65M | |
| Stock Issued | $42M | · | · | $126M | · | · | · | |
| Net Stock Activity | $42M | · | · | $126M | · | · | · | |
| Financing Cash Flow | $155M | $19M | $70M | $127M | $232.0K | $292M | $121M | |
| Net Change in Cash | $97M | $-2M | $-16M | $-96M | $80M | $62M | $36M | |
| Taxes Paid | $0 | $0 | $220.0K | $613.0K | · | · | · | |
| Free Cash Flow | $-39M | · | · | · | · | $-61M | · | |
| Levered FCF | $-40M | · | · | · | · | · | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -67.9% | -38.0% | -81.4% | -59.9% | · | -27.4% | · | |
| ROE | -65.8% | -491.2% | -111.6% | -70.6% | · | -19.2% | · | |
| ROIC | -58.6% | -57.8% | -137.0% | -76.1% | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · | 29.4 | · | |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · | 29.0 | · | |
| Interest Coverage | -32.0 | · | · | · | · | · | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.44 | $22.48 | $1.28 | $2.41 | · | $5.70 | · | |
| Cash Flow / Share | $-2.51 | $-13.52 | $-1.20 | $-1.85 | · | · | · | |
| Cash / Share | $4.28 | $23.47 | $0.79 | $1.14 | · | $1.98 | · | |
| EPS (TTM) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | · | |
| Market Cap | $193M | $49M | $1.79B | $10.98B | · | $54.75B | · | |
| P/E | -3.0 | -0.2 | -0.4 | -53.6 | -108.6 | · | · | |
| P/B | 2.5 | 0.4 | 12.2 | 48.9 | · | 155.1 | · | |
| P / Tangible Book | 2.5 | · | · | 48.9 | 84.0 | 155.1 | · | |
| P / Cash Flow | -5.0 | -0.7 | -14.3 | -77.3 | · | -900.4 | · | |
| P / FCF | -5.0 | · | · | · | · | -896.9 | · | |
| Earnings Yield | -33.8% | -535.9% | -269.1% | -1.9% | -0.92% | · | · |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $9M | $8M | $7M | $9M | $8M | $6M | $4M | $36M | $3M | $2M | $33M | $34M | $35M | $31M | $28M | $30M | |
| SG&A Expense | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $2M | $976.0K | $602.0K | $10M | $13M | $12M | $13M | $12M | $13M | |
| Operating Expenses | $12M | $12M | $11M | $13M | $12M | $10M | $7M | $38M | $4M | $3M | $62M | $47M | $47M | $43M | $40M | $43M | |
| Operating Income | $-12M | $-12M | $-11M | $-13M | $-12M | $-10M | $-7M | $-38M | $-4M | $-3M | $-62M | $-47M | $-47M | $-43M | $-40M | $-43M | |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1M | $1M | $815.0K | $499.0K | $78.0K | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | · | · | · | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $898.0K | $668.0K | |
| Other Non-op | $871.0K | $977.0K | $803.0K | $847.0K | $906.0K | $193.0K | $64.0K | $31.0K | $66.0K | $27.0K | $1M | $1M | $521.0K | $723.0K | $986.0K | $210.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | $-60M | $-44M | $-45M | · | $-39M | $-42M | |
| Income Tax | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-126.0K | $0 | $0 | $0 | $-415.0K | $0 | |
| Net Income | $-12M | $-11M | $-10M | $-12M | $-11M | $-10M | $-22M | $-38M | $-6M | $-3M | $-60M | $-44M | $-45M | $-41M | $-38M | $-42M | |
| EPS (Basic) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| EPS (Diluted) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| Shares (Basic) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| Shares (Diluted) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| EBITDA | $-12M | $-12M | · | $-13M | $-12M | $-10M | · | $-6M | $-8M | $-32M | · | $-47M | $-47M | $-43M | · | $-43M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $34M | $98M | $42M | $88M | $101M | $2M | $117M | $105M | $86M | $90M | $96M | $197M | $116M | $106M | $124M | |
| Short-term Investments | $50M | $63M | $20M | $35M | · | · | $0 | $5M | $25M | $54M | $94M | $118M | $50M | $87M | $128M | $140M | |
| Prepaid Expense | $2M | $861.0K | $827.0K | $1M | $3M | $1M | $967.0K | $626.0K | $230.0K | $771.0K | $3M | $6M | $5M | $7M | $7M | $6M | |
| Current Assets | $96M | $98M | $119M | $78M | $92M | $102M | $3M | $123M | $130M | $141M | $188M | $220M | $253M | $212M | $243M | $272M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $673.0K | $759.0K | $844.0K | $930.0K | $943.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $2M | $953.0K | $976.0K | $691.0K | $410.0K | $410.0K | · | · | · | $122.0K | $1M | $684.0K | $490.0K | $612.0K | $734.0K | |
| Total Assets | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Accounts Payable | $1M | $905.0K | $1M | $494.0K | $4M | $2M | $2M | $51.0K | $110.0K | $765.0K | $7M | $4M | $5M | $4M | $3M | $5M | |
| Accrued Liabilities | · | · | · | · | · | · | · | $1M | $2M | $5M | $10M | $16M | $17M | $12M | $14M | $14M | |
| Current Liabilities | $9M | $8M | $10M | $6M | $8M | $7M | $25M | $1M | $2M | $8M | $28M | $33M | $31M | $25M | $24M | $21M | |
| Capital Leases | $1M | $1M | $1M | $1M | · | · | $0 | · | $8M | $16M | $17M | $20M | $23M | $26M | $28M | $20M | |
| Total Liabilities | $42M | $41M | $43M | $39M | $40M | $39M | $57M | $1M | $11M | $24M | $45M | $53M | $54M | $51M | $53M | $40M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $11.0K | $11.0K | $11.0K | $0 | $11.0K | $11.0K | $9.0K | $9.0K | $9.0K | |
| Paid-in Capital | $240M | $239M | $239M | $192M | $191M | $191M | $20M | $818M | $813M | $807M | $802M | $792M | $782M | $701M | $691M | $681M | |
| Retained Earnings | $-182M | $-171M | $-160M | $-150M | $-138M | $-127M | $-117M | $-697M | $-693M | $-686M | $-656M | $-596M | $-552M | $-507M | $-466M | $-428M | |
| AOCI | $-73.0K | $-49.0K | $6.0K | $6.0K | · | · | $0 | $-134.0K | $-139.0K | $-138.0K | $-62.0K | $-200.0K | $-225.0K | $-301.0K | $-468.0K | $-563.0K | |
| Stockholders' Equity | $58M | $69M | $79M | $42M | $53M | $64M | $-97M | $121M | $120M | $120M | $146M | $195M | $229M | $194M | $225M | $253M | |
| Liabilities + Equity | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Shares Outstanding | 23,804,981 | 22,992,291 | 22,902,418 | 18,702,418 | 18,702,418 | 18,702,418 | 1,356,431 | 115,438,119 | 115,312,411 | 114,881,765 | 4,962,997 | 113,966,594 | 113,716,018 | 93,427,990 | 93,093,243 | 92,640,109 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $141.0K | $86.0K | $85.0K | $86.0K | $86.0K | $85.0K | |
| Stock-based Comp | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $-10M | $-5M | $31.0K | $10M | $10M | $10M | $10M | $9M | $11M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Restructuring | · | · | · | · | · | · | · | $100.0K | $500.0K | $10M | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | |
| Operating Cash Flow | $-11M | $-12M | $-7M | $-11M | $-13M | $-7M | $-8M | $43M | $36M | $-5M | $-31M | $-34M | $-27M | $-32M | $-32M | $-35M | |
| CapEx | · | · | $17.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $20M | $-50M | $15M | · | · | · | · | $20M | $30M | $40M | $25M | $-67M | $38M | $42M | $14M | $-39M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-377.0K | $-2M | $48M | $0 | $0 | $107M | $8M | $12M | $5M | $7M | $11.0K | $0 | · | · | $292.0K | $126M | |
| Net Change in Cash | $9M | $-64M | $56M | $-46M | $-13M | $100M | $-274.0K | $-16M | $7M | $2M | $-6M | $-101M | $81M | $10M | $-18M | $53M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $-131.0K | $1.0K | · | · | $-390.0K | $0 |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.0% | -10.2% | · | -11.7% | -10.1% | -8.2% | · | -2.2% | -2.9% | -15.6% | · | -16.3% | -18.8% | -17.3% | · | -13.8% | |
| ROE | -20.8% | -16.4% | · | -14.6% | -13.1% | -11.1% | · | -2.6% | -3.5% | -19.3% | · | -19.7% | -23.4% | -21.4% | · | -16.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -24.0% | -20.6% | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 12.2 | · | 12.9 | 12.0 | 14.3 | · | 86.8 | 55.1 | 18.5 | · | 6.7 | 8.3 | 8.5 | · | 13.1 | |
| Quick Ratio | 10.7 | 12.0 | · | 12.7 | 11.6 | 14.1 | · | 86.3 | 54.9 | 18.4 | · | 6.5 | 8.1 | 8.1 | · | 12.7 | |
| Interest Coverage | · | · | · | · | · | -7.2 | · | · | · | · | · | · | · | · | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.42 | $2.98 | · | $2.24 | $2.84 | $3.42 | · | $1.05 | $1.04 | $1.05 | · | $1.71 | $2.01 | $2.07 | · | $2.73 | |
| Cash Flow / Share | · | $-0.49 | · | · | · | $-1.84 | · | · | · | $-0.39 | · | · | · | $-0.34 | · | · | |
| Cash / Share | $1.81 | $1.50 | · | $2.27 | $4.73 | $5.40 | · | $1.01 | $0.91 | $0.75 | · | $0.84 | $1.73 | $1.24 | · | $1.34 | |
| EPS (TTM) | $-0.66 | $-0.79 | · | $-20.52 | $-48.04 | $-51.69 | · | $-75.80 | $-48.03 | $-44.25 | · | $-1.63 | $-1.74 | $-1.95 | · | $-2.80 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-44M | $-44M | · | $-55M | $-82M | $-76M | · | $-107M | $-113M | $-153M | · | $-169M | $-167M | $-166M | · | $-189M | |
| Market Cap | $97M | $133M | · | $108M | $50M | $150M | · | $2.15B | $1.92B | $1.99B | · | $5.64B | $8.89B | $8.47B | · | $16.81B | |
| P/E | -6.2 | -7.3 | · | -0.3 | -0.1 | -0.2 | · | -0.2 | -0.3 | -0.4 | · | -30.3 | -44.9 | -46.5 | · | -64.8 | |
| P/B | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Tangible Book | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Cash Flow | · | -11.5 | · | · | · | -20.2 | · | · | · | -45.0 | · | · | · | -263.6 | · | · | |
| Earnings Yield | -16.2% | -13.7% | · | -355.0% | -1799.2% | -643.7% | · | -407.4% | -288.8% | -254.8% | · | -3.3% | -2.2% | -2.1% | · | -1.5% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Beneficio neto | $-43M | $-69M | $-190M | $-169M | $-172M |
| EPS Diluido | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 12.2 | 22.6 | 6.6 | 10.0 | · |
| Ratio Rápido | 12.1 | 22.6 | 6.5 | 9.6 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-39M | · | · | · | · |
Propietarios institucionales (13F) 57 declarantes · $75.8M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
57
Valor en tenencia
$75.8M
Nuevas posiciones
9
Posiciones cerradas
11
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 9 (-6 vs trimestre anterior) | 11 (+4 vs trimestre anterior) | 18 (+2 vs trimestre anterior) | 9 (+2 vs trimestre anterior) | -548K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | $52 426 382 | 12 881 175 | 69,20% | Acciones |
| RTW INVESTMENTS, LP | $5 291 000 | 1 300 000 | 6,98% | Acciones |
| VANGUARD GROUP INC | $2 471 147 | 292 790 | 3,26% | Acciones |
| Alyeska Investment Group, L.P. | $2 330 836 | 572 687 | 3,08% | Acciones |
| Siren, L.L.C. | $1 773 698 | 435 798 | 2,34% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $1 622 758 | 398 712 | 2,14% | Acciones |
| Ikarian Capital, LLC | $1 465 201 | 360 000 | 1,93% | Acciones |
| UBS Group AG | $1 066 873 | 262 131 | 1,41% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $607 859 | 149 351 | 0,80% | Acciones |
| MARSHALL WACE, LLP | $566 549 | 139 201 | 0,75% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $464 287 | 114 037 | 0,61% | Acciones |
| Woodline Partners LP | $407 000 | 100 000 | 0,54% | Acciones |
| ADAR1 Capital Management, LLC | $407 000 | 100 000 | 0,54% | Acciones |
| WHI TRUST Co LLC | $396 797 | 97 493 | 0,52% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $395 457 | 97 164 | 0,52% | Acciones |
| CITADEL ADVISORS LLC | $389 792 | 95 772 | 0,51% | Acciones |
| BOOTHBAY FUND MANAGEMENT, LLC | $375 502 | 92 261 | 0,50% | Acciones |
| Verdad Advisers, LP | $326 809 | 80 297 | 0,43% | Acciones |
| MORGAN STANLEY | $294 367 | 72 326 | 0,39% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $269 349 | 66 179 | 0,36% | Acciones |
| BlackRock, Inc. | $221 580 | 54 442 | 0,29% | Acciones |
| Fortis Capital Advisors, LLC | $162 800 | 40 000 | 0,21% | Acciones |
| Belpointe Asset Management LLC | $162 800 | 40 000 | 0,21% | Acciones |
| Pale Fire Capital SE | $161 278 | 39 626 | 0,21% | Acciones |
| Squarepoint Ops LLC | $157 814 | 38 775 | 0,21% | Acciones |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $132 275 | 32 500 | 0,17% | Acciones |
| Stonepine Capital Management, LLC | $122 597 | 30 122 | 0,16% | Acciones |
| Connor, Clark & Lunn Investment Management Ltd. | $122 128 | 30 007 | 0,16% | Acciones |
| Trexquant Investment LP | $121 030 | 29 737 | 0,16% | Acciones |
| STATE STREET CORP | $107 896 | 26 510 | 0,14% | Acciones |
| NORTHERN TRUST CORP | $105 165 | 25 839 | 0,14% | Acciones |
| Velan Capital Investment Management LP | $101 750 | 25 000 | 0,13% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $97 057 | 23 847 | 0,13% | Acciones |
| WealthTrust Asset Management, LLC | $83 093 | 20 416 | 0,11% | Acciones |
| Independent Advisor Alliance | $73 769 | 18 125 | 0,10% | Acciones |
| RBF Capital, LLC | $70 781 | 17 391 | 0,09% | Acciones |
| Quadrature Capital Ltd | $67 265 | 16 527 | 0,09% | Acciones |
| GOLDMAN SACHS GROUP INC | $65 340 | 16 054 | 0,09% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $64 991 | 15 958 | 0,09% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57 879 | 14 221 | 0,08% | Acciones |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $50 875 | 12 500 | 0,07% | Acciones |
| Sigma Planning Corp | $41 380 | 10 167 | 0,05% | Acciones |
| FMR LLC | $31 770 | 7 806 | 0,04% | Acciones |
| Tower Research Capital LLC (TRC) | $10 419 | 2 560 | 0,01% | Acciones |
| Steward Partners Investment Advisory, LLC | $9 015 | 2 215 | 0,01% | Acciones |
| Vanguard Global Advisers, LLC | $2 951 | 725 | 0,00% | Acciones |
| BARCLAYS PLC | $1 233 | 303 | 0,00% | Acciones |
| Strengthening Families & Communities, LLC | $1 091 | 268 | 0,00% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $212 | 52 | 0,00% | Acciones |
| JPMORGAN CHASE & CO | $211 | 50 | 0,00% | Acciones |
Activistas y propietarios del %+ 5 4 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, Srinivas Akkaraju ×4 presentaciones | 22 de mayo de 2026 | 54,20% | Enmienda | · | SEC |
| ElevateBio, LLC (2) | 5 de agosto de 2022 | · | Presentación inicial | · | SEC |
| F2 MG Ltd. (2), F2-TPO Investments, LLC (2), F2 MC, LLC (2), F2 Capital I 2020 LLC (2), F2 Bioscience AV 2022 LLC (2), Globeways Holdings Ltd. (2), Globeways Holdings II Ltd. (2), Morana Jovan-Embiricos (2) | 5 de agosto de 2022 | · | Presentación inicial | · | SEC |
| ElevateBio LLC (2) | 13 de agosto de 2020 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 32 insiders · 14 directivos · 20 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Andrew Oxtoby | President and Chief Executive Officer | 19 de marzo de 2026 A | · | 0 | 0 | $0 |
| Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | 21 de febrero de 2025 S | 49 129 | 0 | 0 | $0 |
| Diana Brainard | Chief Executive Officer | 19 de noviembre de 2024 S | 723 363 | 0 | 0 | $0 |
| Liisa Ann Bayko | Chief Financial Officer | 20 de julio de 2026 A | · | 0 | 0 | $0 |
| Matthew Gall | Chief Financial Officer | 19 de marzo de 2026 A | · | 0 | 0 | $0 |
| Amy O'Leary Vandekop | VP, Corporate Controller | 27 de agosto de 2026 A | · | 0 | 0 | $0 |
| Matthew Feinsod | Chief Medical Officer | 19 de marzo de 2026 A | 4 030 | 0 | 0 | $0 |
| Brett R Hagen | Chief Accounting Officer | 19 de marzo de 2026 A | 0 | 0 | 1 | $-12 869 |
| Edward Miller | General Counsel | 21 de febrero de 2025 S | 6 517 | 0 | 0 | $0 |
| Cintia Piccina | Chief Commercial Officer | 3 de julio de 2023 A | 147 000 | 0 | 0 | $0 |
| Ann M. Leen | Chief Scientific Officer | 2 de febrero de 2023 A | 124 006 | 0 | 0 | $0 |
| Jeroen B Van Beek | Chief Commercial Officer | 16 de noviembre de 2022 S | 333 726 | 0 | 0 | $0 |
| Ercem Atillasoy | This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer T | 21 de octubre de 2022 S | 131 372 | 0 | 0 | $0 |
| Agustin Melian | Chief Medical Officer | 4 de octubre de 2021 S | 453 529 | 0 | 0 | $0 |
| Laurie Keating | Consejero | 1 de agosto de 2026 A | · | 0 | 0 | $0 |
| Napoleone Ferrara | Consejero | 3 de junio de 2026 A | 504 000 | 0 | 0 | $0 |
| Michael Dybbs | Consejero | 3 de junio de 2026 A | · | 0 | 0 | $0 |
| Morana Jovan-Embiricos | Consejero | 3 de junio de 2026 A | 100 197 | 0 | 0 | $0 |
| David Hallal | Consejero | 3 de junio de 2026 A | 2 143 662 | 0 | 0 | $0 |
| Anthony P Adamis | Consejero | 3 de junio de 2026 A | · | 0 | 0 | $0 |
| Srinivas Akkaraju | Consejero | 3 de junio de 2026 A | 11 444 503 | 0 | 0 | $0 |
| Leone D Patterson | Consejero | 3 de junio de 2026 A | · | 0 | 0 | $0 |
| Samir Chandrakant Patel | Consejero | 10 de abril de 2025 A | 100 800 | 0 | 0 | $0 |
| Derek N. Adams | Consejero | 6 de junio de 2024 A | 70 000 | 0 | 0 | $0 |
| Malcolm Brenner | Consejero | 6 de junio de 2024 A | 100 197 | 0 | 0 | $0 |
| Juan Vera | Consejero | 6 de junio de 2024 A | 2 409 928 | 0 | 0 | $0 |
| Shawn Tomasello | Consejero | 6 de junio de 2024 A | 70 000 | 0 | 0 | $0 |
| Jeffrey S Bornstein | Consejero | 6 de junio de 2024 A | 110 197 | 0 | 0 | $0 |
| ElevateBio, LLC | Consejero | 28 de julio de 2022 A | 16 674 766 | 0 | 0 | $0 |
| ANSBERT GADICKE | Consejero | 28 de julio de 2022 A | 16 674 766 | 0 | 0 | $0 |
| John Robert Wilson | Consejero | 25 de mayo de 2021 A | 3 164 954 | 0 | 0 | $0 |
| Gilead Sciences, Inc. | Propietario del 10% | 27 de junio de 2023 P | 16 635 286 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 5 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IWC · iShares Trust | 0,01% | 25 753 SH | 11 de septiembre de 2026 | Diario |
| DCOR · Dimensional ETF Trust | 0,00% | 3 296 NS | 31 de julio de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 137 373 SH | 19 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 255 337 SH | 19 de agosto de 2026 | Diario |
| DFAC · Dimensional ETF Trust | 0,00% | 2 614 NS | 31 de julio de 2026 | N-PORT |
KLRS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 14 analistas
COMPRA
Objetivo mediano
$20.00
+640,7%
6 42,9%
Compra fuerte
6 42,9%
Compra
2 14,3%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
7 analistas · 2026-09-30Objetivo medio $18.71 +593,1%
← Por Debajo de Todos los Objetivos
Precio Actual $2.70
Mín$7.00
Media$18.71
Máx$25.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| ACET | · | -0.5 | · | · | · | · |
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| CNTB | $159M | -2.8 | -99.8% | -86687.5% | -97.9% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 11, 2026